Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat + bortezomib + dexamethasone vs placebo + bortezomib + dexamethasone in relapsed multiple myeloma
2009-015507-52Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple myeloma (MM) comparing Panobinostat + bortezomib + dexamethasone with Placebo + bortezomib + dexamethasone (2 arms). Primary endpoint: Progression-free survival. Started Oct 2009; status: completed.
02
Drugs
panobinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2009-015507-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015507-52.